Vanda Pharmaceuticals Inc.
Fanapt Launches in the U.S.
Published in Mental Health Weekly Digest, January 25th, 2010
In October 2009, Vanda and Novartis Pharma AG entered into an agreement, pursuant to which Novartis has exclusive U.S. and Canadian commercialization rights to Fanapt™. Under this agreement, Vanda received an upfront payment of $200 million and is eligible for future payments totaling up to $265 million upon the achievement of certain commercial and development milestones for Fanapt™, as...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest
More Articles from Mental Health Weekly Digest
- Boston University Medical Center
Angiotensin receptor blockers associated with lower risk of Alzheimer's disease - Children's Hospital Boston
Research adds to evidence that autism is a brain 'connectivity' disorder - Columbia University Medical Center
Surplus of serotonin receptors may explain failure of antidepressants in some patients - Massachusetts General Hospital
Words used to describe substance-use patients can alter attitudes, contribute to stigma - New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Reducing dosage of Parkinson's drugs can cause symptoms similar to those of cocaine withdrawal - NIH/National Institute on Alcohol Abuse and Alcoholism
Molecule repairs alcohol metabolism enzyme - More from this issue of Mental Health Weekly Digest
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
